Effect on prostaglandin E2 and leukotriene B4 levels by local administration of glucocorticoid in human masseter muscle myalgia.
Our aim was to determine whether masseter muscle (M) and plasma (P) levels of prostaglandin E2 (PGE2) or leukotriene B4 (LTB4) are influenced by local glucocorticoid administration and whether such changes would be associated with corresponding changes in local pain or hyperalgesia. Eighteen patients with fibromyalgia and 15 with local masseter myalgia were examined immediately before and 2 weeks after intramuscular administration of glucocorticoid with regard to masseter muscle resting pain and tenderness to palpation, pressure pain threshold, maximum voluntary mouth opening (MVM), and pain on maximum voluntary mouth opening. The primary criteria for inclusion were presence of pain for a period of at least 3 months and tenderness to digital palpation in the masseter muscle region. At both visits microdialysis samples were obtained from the masseter muscle, and venous blood was collected for analysis of PGE2 and LTB4. Dialysate levels of M-PGE2 did not change significantly after glucocorticoid administration, but reduction of masseter resting pain and increase of MVM were associated with decrease of M-PGE2 in the patients with fibromyalgia. Dialysate levels of M-LTB4 increased in both groups. In the patients with local myalgia the plasma level of LTB4 also increased, and this increase was associated with a decrease of pain and masseter tenderness. In conclusion, this study shows that reduction of masseter level of PGE2 after intramuscular glucocorticoid administration is associated with a decrease of resting pain in patients with fibromyalgia. In addition, the masseter muscle level of LTB4 increases in patients with fibromyalgia and local myalgia.
Hedenberg-Magnusson
Britt
B
Clinical Oral Physiology, Institute of Odontology, Karolinska Institutet, Huddinge, Sweden. britt.hedenberg-magnusson@ofa.ki.se
Ernberg
Malin
M
Alstergren
Per
P
Kopp
Sigvard
S
D000328:Adult; D000368:Aged; D015232:Dinoprostone / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D005157:Facial Pain / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy* / Q000378:metabolism; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007273:Injections, Intramuscular; D007975:Leukotriene B4 / Q000032:analysis / Q000097:blood / Q000378:metabolism*; D008297:Male; D008406:Masseter Muscle; D008775:Methylprednisolone / Q000008:administration & dosage*; D008875:Middle Aged; D010147:Pain Measurement; D011863:Radioimmunoassay; D018709:Statistics, Nonparametric; D013706:Temporomandibular Joint Dysfunction Syndrome / Q000188:drug therapy* / Q000378:metabolism
D005938:Glucocorticoids; D007975:Leukotriene B4; D015232:Dinoprostone; D008775:Methylprednisolone